Goldman Sachs has continued its extraordinary run — up 7% on the week to $1,064.58 — but the options market is sending its most defensive signal in months, a contrast that defines this week's setup.
The put/call ratio has climbed to 0.993, now more than two standard deviations above its 20-day mean of 0.892. That z-score of 2.10 is the most elevated reading this column has tracked across the recent rally, and it marks a meaningful escalation from the 1.8 standard deviations flagged in Monday's stock report. Each week the stock has pushed higher, options traders have added more downside cover. The PCR's 52-week range runs from 0.80 to 1.34, so the current level is not yet extreme in absolute terms — but the direction of travel, consistently higher over the past three weeks despite a 15% monthly gain in the underlying, tells a story of uneasy participation. Investors are buying the stock and hedging it at the same time.
The lending market, by contrast, carries no tension at all. Availability has actually expanded further — now at an extraordinary 8,467% — meaning the pool of shares available to borrow dwarfs the short position by a factor of nearly 85 to one. Cost to borrow collapsed to 0.18% on Tuesday, down more than 40% on the week and less than half its level of a month ago. Short interest slipped 4% in a single session to 2.2% of the free float, where it has been anchored for weeks. There is no short-side pressure in this stock. The borrow market is saying one thing; options traders are saying something different.
The Street's read on Goldman has stabilised, though most of the notable analyst action is now six to eight weeks old. After a wave of target cuts across early April — Wells Fargo, BofA, and Jefferies all trimmed on macro concerns — Citigroup's Keith Horowitz moved his target up sharply to $930 on May 8, and BMO lifted to $972 on April 20. The consensus rating remains a buy, with six active buy-equivalent ratings. The practical problem is that Goldman has now traded through most of those price targets: at $1,064, it is above the Citigroup, UBS, and BMO targets and approaching Wells Fargo's $1,000 mark. B of A Securities, at $1,050, is also now below the current price. Only Jefferies, with a $1,049 target, and Wells Fargo come close. The P/E multiple has re-rated by nearly 2.5 points over 30 days to 17.2x. The P/B ratio has expanded by 0.41 points in the same window to 2.79x — a meaningful valuation move for a bank. Dividend yield registers in the 92nd percentile on ORTEX's factor scoring, though that data reflects 2022-era dividend history, so the precise yield figure should be treated as directional rather than precise.
Insider activity adds a mildly cautionary note. CFO Denis Coleman sold just under $6.7 million of stock across four transactions on May 14, with Goldman trading in the $972-$975 range at the time. The stock has since added another ~9%. The Chief Legal Officer also sold roughly $3 million earlier in May. Neither trade carries high significance scores, and both are consistent with routine plan-driven sales rather than a directional call. Still, the cluster of selling at prices well below where the stock trades today is worth registering.
Morgan Stanley, the closest peer, matched Goldman's momentum with a 6.6% weekly gain. Jefferies added 4.4%. By contrast, Piper Sandler fell 4.3% on the week, and Invesco and Artisan Partners both closed marginally lower — a divergence that suggests the rally is concentrated in the larger capital-markets names rather than the broader financial sector.
The next scheduled catalyst is Goldman's Q2 earnings on July 14. With the stock trading above most Street targets and options traders steadily buying protection into new highs, how the firm characterises its pipeline — particularly M&A advisory and fixed-income trading volumes — will determine whether the valuation re-rating has room to run or has already priced the good news in.
See the live data behind this article on ORTEX.
Open GS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
